UNITED THERAPEUTICS CORPORATION

NASDAQ: UTHR (United Therapeutics Corporation)

Last update: 18 hours ago

549.57

3.61 (0.66%)

Previous Close 545.96
Open 545.96
Volume 327,850
Avg. Volume (3M) 514,606
Market Cap 23,327,451,136
Price / Earnings (TTM) 20.34
Price / Earnings (Forward) 20.04
Price / Sales 8.25
Price / Book 3.96
52 Weeks Range
272.12 (-50%) — 609.35 (10%)
Earnings Date 29 Jul 2026
Profit Margin 40.44%
Operating Margin (TTM) 48.19%
Diluted EPS (TTM) 25.11
Quarterly Revenue Growth (YOY) 17.20%
Quarterly Earnings Growth (YOY) 5.10%
Total Debt/Equity (MRQ) 2.94%
Current Ratio (MRQ) 5.46
Operating Cash Flow (TTM) 1.41 B
Levered Free Cash Flow (TTM) 825.79 M
Return on Assets (TTM) 12.93%
Return on Equity (TTM) 19.94%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Mixed Bullish
Drug Manufacturers - Specialty & Generic (Global) Mixed Bullish
Stock United Therapeutics Corporation Bullish Bullish

AIStockmoo Score

-0.3
Analyst Consensus 2.0
Insider Activity -5.0
Price Volatility -0.5
Technical Moving Averages 2.5
Technical Oscillators -0.5
Average -0.30

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
UTHR 23 B - 20.34 3.96
NBIX 16 B - 24.58 4.84
HCM 2 B - 4.14 1.53
VTRS 19 B 2.91% - 1.29
KNSA 4 B - 57.02 6.59
BCRX 2 B - - 56.59

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Mid Core
% Held by Insiders 1.75%
% Held by Institutions 100.69%

No data within this time range.

Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
EDGEMOND JAMES - 547.69 -10,000 -5,476,900
MAHON PAUL A - 547.69 -8,300 -4,545,827
ROTHBLATT MARTINE A - 546.77 -38,000 -20,777,260
Aggregate Net Quantity -56,300
Aggregate Net Value ($) -30,799,987
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 547.08
Name Holder Date Type Quantity Price Value ($)
ROTHBLATT MARTINE A Officer 05 Jun 2026 Automatic sell (-) 9,500 549.87 5,223,765
ROTHBLATT MARTINE A Officer 05 Jun 2026 Option execute 9,500 - -
MAHON PAUL A Officer 04 Jun 2026 Automatic sell (-) 8,300 547.69 4,545,827
MAHON PAUL A Officer 04 Jun 2026 Option execute 8,300 - -
ROTHBLATT MARTINE A Officer 04 Jun 2026 Automatic sell (-) 9,500 547.69 5,203,055
ROTHBLATT MARTINE A Officer 04 Jun 2026 Option execute 9,500 - -
EDGEMOND JAMES Officer 04 Jun 2026 Automatic sell (-) 10,000 547.69 5,476,900
EDGEMOND JAMES Officer 04 Jun 2026 Option execute 10,000 - -
ROTHBLATT MARTINE A Officer 03 Jun 2026 Automatic sell (-) 9,500 549.47 5,219,965
ROTHBLATT MARTINE A Officer 03 Jun 2026 Option execute 9,500 - -
ROTHBLATT MARTINE A Officer 02 Jun 2026 Automatic sell (-) 9,500 540.05 5,130,475
ROTHBLATT MARTINE A Officer 02 Jun 2026 Option execute 9,500 - -
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria